Study AG348-C-007 is a multicenter study designed to evaluate the efficacy and safety of treatment with AG-348 in a minimum of 20, with up to 40, subjects with pyruvate kinase deficiency (PKD), who are regularly receiving blood transfusions. The study is comprised of two parts. During the Part 1 Dose Optimization Period of the study, all participants will start on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each participant's dose will be optimized individually, up to a maximum dose of 50 milligrams (mg), twice daily. During the Part 2 Fixed-Dose Period, participants will receive AG-348 at their optimized dose from Part 1.
Name: AG-348
Allocation: N/A
Single Group Assignment
There is one SNP
Exclusion Criteria: - Homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene; - Significant medical condition that confers an unacceptable risk to participate in the study, and/or that could confound the interpretation of the study data; - History of transfusions occurring on average more frequently than once every 3 weeks during the 52 weeks prior to date of informed consent; - Splenectomy scheduled during the study treatment period or have undergone splenectomy within 12 months prior to signing informed consent; - Currently enrolled in another therapeutic clinical trial. --- R479H ---